{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rammensee HG"],"funding":["University Hospital Tübingen","University of Tübingen","Deutsche Forschungsgemeinschaft","Medical Faculty at the University of Tübingen","Ernst-Jung Stiftung"],"pagination":["428"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8146137"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(5)"],"pubmed_abstract":["We describe the results of two vaccinations of a self-experimenting healthy volunteer with SARS-CoV-2-derived peptides performed in March and April 2020, respectively. The first set of peptides contained eight peptides predicted to bind to the individual's HLA molecules. The second set consisted of ten peptides predicted to bind promiscuously to several HLA-DR allotypes. The vaccine formulation contained the new TLR 1/2 agonist XS15 and was administered as an emulsion in Montanide as a single subcutaneous injection. Peripheral blood mononuclear cells isolated from blood drawn before and after vaccinations were assessed using Interferon-γ ELISpot assays and intracellular cytokine staining. We detected vaccine-induced CD4 T cell responses against six out of 11 peptides predicted to bind to H"],"journal":["Vaccines"],"pubmed_title":["Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups."],"pmcid":["PMC8146137"],"funding_grant_id":["(“Angewandte Klinische Forschung” (AKF) program","(\"Angewandte Klinische Forschung\" (AKF) program","generic funding","Ernst Jung-Preis für Medizin 2016","EXC 2180 (390900677)"],"pubmed_authors":["Heidu S","Yang J","Klein R","Reth M","Planz O","Loffler MW","Gouttefangeas C","Preuß B","Bosmuller H","Hoffmann H","Wiesmuller KH","Rammensee HG","Haen SP","Tabatabai G","Nelde A","Schindler M","Walz JS"],"additional_accession":[]},"is_claimable":false,"name":"Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups.","description":"We describe the results of two vaccinations of a self-experimenting healthy volunteer with SARS-CoV-2-derived peptides performed in March and April 2020, respectively. The first set of peptides contained eight peptides predicted to bind to the individual's HLA molecules. The second set consisted of ten peptides predicted to bind promiscuously to several HLA-DR allotypes. The vaccine formulation contained the new TLR 1/2 agonist XS15 and was administered as an emulsion in Montanide as a single subcutaneous injection. Peripheral blood mononuclear cells isolated from blood drawn before and after vaccinations were assessed using Interferon-γ ELISpot assays and intracellular cytokine staining. We detected vaccine-induced CD4 T cell responses against six out of 11 peptides predicted to bind to H","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2026-04-08T08:12:12.593Z","creation":"2022-02-10T14:35:30.354Z"},"accession":"S-EPMC8146137","cross_references":{"pubmed":["33923363"],"doi":["10.3390/vaccines9050428"]}}